peptides and FAQ

Carnivore adaptation involves transient metabolic shifts. Elevated cortisol, temporary insulin resistance, mitochondrial enzyme upregulation, electrolyte recalibration. Introducing multiple peptides during this phase can obscure whether symptoms (fatigue, brain fog, irritability) are from adaptation or peptide side effects. Stick to one well-tolerated peptide (typically a short-acting GHRP or MK 677) during weeks 1–4. Add autophagy or cognitive peptides only after fasting insulin drops below 6 μIU/mL and adaptation symptoms resolve.

OMAD carnivore creates a 22–23 hour fasted window, which is ideal for sequential peptide stacking. Dose autophagy peptides (Thymalin, epithalon) at hour 12–14 of the fast. Dose short-acting GHRPs 90 minutes before your single meal. If using MK 677, take it 2–3 hours after your meal in the evening to align the GH surge with sleep without interfering with nutrient absorption.

Nausea from GHRPs on carnivore typically indicates delayed gastric emptying compounded by high dietary fat. Carnivore meals are often 60–75% fat by calorie, which naturally slows gastric transit. GHRPs further delay emptying through ghrelin receptor agonism. Solution: reduce fat percentage in your immediate post-peptide meal to 50–60% calories from fat, emphasize leaner cuts (sirloin, bison, white fish) for the first meal, and ensure you're dosing the GHRP a full 90–120 minutes before eating. Not 30–60 minutes.

Don't. Postprandial insulin blunts growth hormone release by 40–60% even on carnivore, where protein-induced insulin spikes are modest (typically 15–25 μIU/mL peak vs. 50–80 μIU/mL on high-carb meals). The GH-suppressing effect of insulin operates on a dose-response curve. Even low insulin levels reduce GH pulse amplitude. Dose your GHRP 90–120 minutes before eating instead, allowing the GH peak to coincide with the meal's anabolic phase.

Administer peptides on the morning of non-injection days to maximize separation from the testosterone peak. Most men on twice-weekly protocols inject Monday and Thursday evenings. Schedule peptides for Tuesday, Wednesday, Friday, and Saturday mornings. This creates a 12–16 hour separation window from the previous testosterone dose and ensures the peptide works during a lower androgen floor. If training schedule requires flexibility, the minimum acceptable window is six hours. Never less.

The GH pulse is already blunted. Leucine-mTOR feedback begins within 15–20 minutes of protein ingestion. You won't reverse the interference by skipping your next meal; instead, extend your fasting window before the next GH secretagogue dose to restore full pituitary responsiveness. One meal doesn't ruin a protocol, but repeated leucine interference over weeks compounds into measurably lower IGF-1 levels. If this becomes a pattern, consider switching to morning fasted dosing instead of post-workout.

MK 677 maintains elevated IGF-1 for 12–24 hours, but peak GH secretion occurs 2–3 hours post-dose when administered orally. Apply red light therapy 90–120 minutes after dosing to target the GH peak window, not the extended IGF-1 tail. The synergistic amplification occurs during active signaling. Treating during the maintenance phase produces baseline photobiomodulation benefits without the multiplicative peptide interaction. If running MK 677 as a daily evening dose, schedule red light sessions 90 minutes post-administration before sleep.

Take D3 30–60 minutes before your first peptide dose of the day. Typically morning administration for protocols using Tesofensine or KPV. D3's genomic effects last 12–18 hours, so a single morning dose primes receptors for peptide administrations throughout the day. Taking additional D3 doses before each peptide injection risks exceeding the 10,000 IU daily upper limit and doesn't provide additional synergy. VDR upregulation plateaus once calcitriol reaches saturation in target tissues.

Introduce peptides at your current AIP timeline point and reset the measurement clock to Week 0 for peptide assessment. You've already documented AIP-driven symptom changes (or lack thereof). Adding peptides now creates a new baseline from which to measure immune modulation independent of further dietary changes. Continue AIP compliance unchanged while initiating Thymalin or KPV dosing, then track symptom and lab marker progression from peptide introduction forward. The limitation: you cannot retroactively isolate what AIP alone contributed before peptides, but you can measure additive peptide benefit from this point.

Group peptides by receptor class, then create a daily administration timeline based on half-life and pathway synergy. Example for a cognitive enhancement stack: administer Cerebrolysin (longest half-life, 6–8 hours) first, wait 2 hours, dose Dihexa (shorter half-life, different mechanism), wait another 3 hours, then finish with P21 in the evening. Never exceed three compounds from the same receptor family in a single 24-hour period. Beyond that, you're saturating pathways without additional benefit.

No. Two weeks is insufficient for tissue-level adaptations to manifest. BPC-157 and TB-500 work by recruiting repair cells and synthesizing new collagen matrix, processes that require 4–6 weeks to produce measurable structural changes in tendons or fascia. Starting peptides in the final taper weeks may reduce acute inflammation slightly, but it will not reverse chronic overuse injuries or provide meaningful injury prevention. The optimal window to begin peptide protocols is at the start of the build phase (8–12 weeks out from race day), allowing enough time for cumulative tissue remodeling effects to develop before peak training stress.

The peptide-induced GH pulse mobilizes free fatty acids for energy, but some individuals experience transient hypoglycemia during the 30-minute post-injection fasting window. If this occurs consistently, move the peptide dose to immediately before bed instead of morning. The bedtime protocol preserves the GH amplification without the fasted-state metabolic demand. Do not break the fasting window with food; doing so suppresses ghrelin receptor activity and cuts peptide efficacy by 50–70%.

Don't. BPC-157 requires pre-workout timing; GH secretagogues require post-workout fasted timing. Combining them into one injection forces you to choose suboptimal timing for at least one compound. Additionally, mixing peptides in the same syringe increases reconstitution complexity and contamination risk. Each peptide should be reconstituted in its own vial with bacteriostatic water, drawn separately, and administered at the physiologically appropriate time.

MK 677 creates baseline GH elevation over 24 hours rather than acute pulses, so daily timing relative to a single training session matters less than consistency. Most users dose MK 677 before bed to leverage the nocturnal GH pulse for recovery, but morning dosing 90–120 minutes before training can create modest intra-workout GH elevation. The compound's value is multi-session recovery support. Not acute timing synergy like GHRP-2 or ipamorelin.

After the initial 16-week assessment phase, transition to maintenance dosing for peptides and selective AIP compliance for confirmed trigger foods only. Thymalin maintenance typically runs 10mg twice weekly for 4 weeks every 3–4 months (cyclical dosing matches natural thymic peptide secretion patterns). KPV can transition to 500mcg 3–4 times weekly instead of daily. AIP reintroduction testing completed during Weeks 13–20 identifies specific foods that trigger symptoms. Eliminate those permanently while reintroducing tolerated foods. The long-term framework: peptides maintain immune regulation, AIP maintains antigen avoidance for confirmed triggers, both together sustain the lowest inflammatory load.

Measure it. Consumer-grade spectrometers (under $200) can verify wavelength accuracy and irradiance at skin-level distance. Devices marketed for skincare typically output 5–12 mW/cm². Insufficient for mitochondrial cytochrome c oxidase activation required for peptide synergy. Research-grade LED panels and clinical devices output 25–50 mW/cm². If your device measures below 20 mW/cm², increase exposure duration proportionally to reach 4–8 J/cm² total fluence, but recognize that sessions exceeding 15 minutes lose adherence feasibility in daily protocols.

Dose it as soon as you remember if you're still within the workout window or immediately after finishing. The primary benefit. Exercise-induced tissue perfusion. Diminishes rapidly post-training as blood flow normalises, but residual capillary dilation persists for 60–90 minutes. Taking BPC-157 six hours later at rest provides minimal localisation benefit compared to the pre-workout window, so the closer you can get to active tissue stress, the better.

Rotate between peptides targeting different receptor classes every 10–14 days instead of using rest periods. For example, alternate between GHRP-2 (ghrelin receptor) and CJC-1295 (GHRH receptor) every two weeks. This prevents single-receptor exhaustion while maintaining continuous growth hormone pathway stimulation. Expect approximately 15–20% lower peak efficacy compared to properly cycled protocols, but this is the best compromise when uninterrupted administration is required.

No. Early symptom improvement doesn't confirm complete immune modulation or identify residual dietary triggers. Thymalin-driven Treg expansion continues through Week 12, and early subjective improvement often precedes objective lab marker normalization. Complete the 12-week peptide phase with lab tracking at Week 8 and Week 12. If inflammatory markers normalize fully and symptoms remain stable through Week 12, you have evidence that peptides alone may be sufficient. But a 30-day AIP trial starting Week 13 still adds diagnostic value by confirming whether any dietary antigens sustain low-grade activation that peptides are compensating for rather than eliminating.

Administer the remainder of the day's protocol as scheduled but skip the next planned dose of the lower-affinity peptide. The competitive binding has already occurred. Adding more of the displaced compound won't reverse it. Resume the normal staggered schedule the following day. Research models show that single-instance timing errors don't cause long-term receptor changes, but repeated mistakes within the same week compound the desensitization effect.